SecBot SecBot
8-K ·Filed May 8, 2026

ANIP

ANI PHARMACEUTICALS INC
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001023024-26-000049
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat and raised guidance, combined with the $100M buyback authorization, signal accelerating Rare Disease momentum and management confidence. Watch for Cortrophin Gel growth trajectory and the acute gouty arthritis sales force deployment in mid-2026 as key catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

ANI Pharmaceuticals reported Q1 2026 revenue of $237.5M (+20.5% YoY) and GAAP diluted EPS of $1.28, beating consensus estimates of $207.6M and $1.30. The company raised full-year 2026 guidance across revenue, adjusted EBITDA, and adjusted EPS, and authorized a $100M share repurchase program through 2029.

Key Financial Metrics

EPS
$1.28
est $1.30 · -1.5%
Revenue
$237.5M
est $207.6M · +14.4% · +20.5% YoY
Rating
strong beat
Guidance
$1,080 million - $1,140 million
raised
Gross Margin
60.6%

Key Facts

  • Q1 2026 net revenue $237.5M, +20.5% YoY vs $197.1M
  • GAAP diluted EPS $1.28 vs $0.69 YoY
  • Adjusted non-GAAP diluted EPS $2.05 vs $1.70 YoY
  • Adjusted non-GAAP EBITDA $63.0M, +24.1% YoY
  • Cortrophin Gel revenue $75.1M, +42.1% YoY
  • ILUVIEN revenue $19.3M, +19.5% YoY
  • Generics revenue $105.4M, +6.8% YoY
  • Raised FY2026 revenue guidance to $1.08B-$1.14B (from $1.055B-$1.115B)
  • Raised FY2026 adjusted EBITDA guidance to $285M-$300M (from $275M-$290M)
  • Raised FY2026 adjusted diluted EPS guidance to $9.19-$9.69 (from $8.83-$9.34)
  • Authorized $100M share repurchase program through May 2029
  • Cash and cash equivalents $311.2M as of March 31, 2026
  • Operating cash flow $58.4M in Q1 2026

Financial Impact

Revenue beat consensus by ~$30M (14.4%), EPS beat by $0.75 (57.7% on GAAP basis vs $1.30 consensus). Guidance raised across all key metrics.

revenueepsebitdaguidance

Risk Factors

  • Brands revenue declined 50.9% YoY due to demand normalization
  • Gross margin contracted ~230bps YoY (GAAP) due to royalty-bearing product mix
  • Reliance on single-source third-party manufacturing for Cortrophin Gel and ILUVIEN
  • Insurance re-verification seasonality may impact Cortrophin Gel in future quarters

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001023024-26-000049
Document: ani-20260508.htm0001023024-26-000049
Document: 0001023024-26-000049-index-headers.html0001023024-26-000049
Document: 0001023024-26-000049-index.html0001023024-26-000049
Document: 0001023024-26-000049.txt0001023024-26-000049
8-K Data (Synthetic)0001023024-26-000049

Track record

34 reports on ANIP

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 12 went positive at some point.

Filters
  1. Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
  2. Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
  3. Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
  4. Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
  5. Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
  6. Nov 5, 202617d ago 8-K Bullish 6/10 No price data
  7. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  8. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  9. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  10. Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026